Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Anti-CD3 antibodies for type 1 diabetes: beyond expectations.

Bach JF.

Lancet. 2011 Aug 6;378(9790):459-60. doi: 10.1016/S0140-6736(11)60980-X. Epub 2011 Jun 28. No abstract available.

PMID:
21719098
[PubMed - indexed for MEDLINE]
2.

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators.

Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28.

PMID:
21719095
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.

Chatenoud L.

Handb Exp Pharmacol. 2008;(181):221-36. Review.

PMID:
18071948
[PubMed - indexed for MEDLINE]
4.

[One step towards restoration of self-tolerance in human autoimmune diseases].

Chatenoud L.

Med Sci (Paris). 2007 Feb;23(2):167-71. Review. French.

PMID:
17291426
[PubMed - indexed for MEDLINE]
Free Article
5.

[Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes].

Chatenoud L.

Med Sci (Paris). 2006 Jan;22(1):5-6. French. No abstract available.

PMID:
16386207
[PubMed - indexed for MEDLINE]
6.

Can we change the course of beta-cell destruction in type 1 diabetes?

Gale EA.

N Engl J Med. 2002 May 30;346(22):1740-2. No abstract available.

PMID:
12037155
[PubMed - indexed for MEDLINE]
7.

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA.

Diabetes. 2005 Jun;54(6):1763-9.

PMID:
15919798
[PubMed - indexed for MEDLINE]
Free Article
8.

Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies.

Cernea S, Herold KC.

Clin Immunol. 2010 Feb;134(2):121-9. doi: 10.1016/j.clim.2009.09.005.

PMID:
19837003
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Retuning the immune system: the future of type 1 diabetes therapy?

Jones D.

Nat Rev Drug Discov. 2009 Aug;8(8):600-1. doi: 10.1038/nrd2956.

PMID:
19644464
[PubMed - indexed for MEDLINE]
10.

Type 1 diabetes--does suppressing T cells increase insulin?

Lernmark A.

N Engl J Med. 2005 Jun 23;352(25):2642-4. No abstract available.

PMID:
15972873
[PubMed - indexed for MEDLINE]
11.

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group.

Clin Immunol. 2009 Aug;132(2):166-73. doi: 10.1016/j.clim.2009.04.007. Epub 2009 May 14.

PMID:
19443276
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

[Antibodies instead of insulin?].

Anders S, Kühnemund L, Stauch M, Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2010 Mar;39(2):97-8. doi: 10.1002/pauz.201090017. German. No abstract available.

PMID:
20196056
[PubMed - indexed for MEDLINE]
13.

CD3-specific antibodies: a portal to the treatment of autoimmunity.

Chatenoud L, Bluestone JA.

Nat Rev Immunol. 2007 Aug;7(8):622-32. Epub 2007 Jul 20. Review.

PMID:
17641665
[PubMed - indexed for MEDLINE]
14.

[Treatment of diabetes mellitus with biologic therapeutics].

Larsen CM, Mandrup-Poulsen T.

Ugeskr Laeger. 2008 Jun 9;170(24):2134-7. Danish.

PMID:
18565296
[PubMed - indexed for MEDLINE]
15.

Clinical studies. Trying to reset the clock on type 1 diabetes.

Couzin-Frankel J.

Science. 2011 Aug 12;333(6044):819-21. doi: 10.1126/science.333.6044.819. No abstract available.

PMID:
21835995
[PubMed - indexed for MEDLINE]
16.
17.

Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.

Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL.

Diabetes. 2007 Aug;56(8):2103-9. Epub 2007 Apr 24.

PMID:
17456848
[PubMed - indexed for MEDLINE]
Free Article
18.

[CD3-specific antibody-induced T-cell apoptosis and apoptotic cell uptake lead to CD3-specific antibody-induced tolerance].

Perruche S, Saas P.

Med Sci (Paris). 2009 Apr;25(4):325-7. doi: 10.1051/medsci/2009254325. French. No abstract available.

PMID:
19409176
[PubMed - indexed for MEDLINE]
Free Article
19.

Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes.

Bisikirska BC, Herold KC.

Ann N Y Acad Sci. 2004 Dec;1037:1-9. Review.

PMID:
15699486
[PubMed - indexed for MEDLINE]
20.

TRX-4 (TolerRx Inc).

Brown WM.

IDrugs. 2006 Apr;9(4):283-91.

PMID:
16596483
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk